Muticentre study to investigate the efficacy of scalp cooling for the prevention of Myocet/cyclofosfamide-induced alopecia in patients with metastatic breast cancer. MyCap study
Completed
- Conditions
- haaruitval t.g.v. chemotherapiealopeciahair loss
- Registration Number
- NL-OMON35380
- Lead Sponsor
- Stichting DIADOC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 70
Inclusion Criteria
* Female breast cancer patients, treated with Myocet and cyclophosphamide containing chemotherapy.
* Life expectancy * 12 weeks.
* ECOG performance scale * 2.
* Age 18 years and above.
Exclusion Criteria
* Allopecia prior to start of the study.
* Simultaneously or shortly after study start: planned skull irradiation (if allopecia is expected).
* Severely disturbed liver enzymes (see protocol for details).
* Hair extensions
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Allopecia measured by trichometry.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Subjective severity of allopecia.</p><br>